Small-molecule inhibitor and application thereof in inhibiting activity of deoxyhydroxyputrescine lysine synthase
By developing new small molecule inhibitors, the problem of lack of DHS activity inhibitors in the prior art has been solved, effective inhibition of DHS is achieved, and treatment strategies for cancers with high expression of DHS and eIF5A are provided.
Patent Information
- Application Number
- CN202310643064.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The lack of effective small molecule inhibitors in the prior art to inhibit deoxyhydroxyputrescyl lysine synthase (DHS) activity, resulting in insufficient therapeutic strategies for cancers with high expression of DHS and eIF5A, such as neuroblastoma, colon cancer, etc. .
A novel small molecule inhibitor was developed to ensure the effectiveness of the inhibitor by constructing DHS prokaryotic gene plasmids, expressing and purifying DHS fusion proteins, verifying inhibitor activity, and verifying the covalentity of MALDI-TOF.
This inhibitor showed good inhibitory effect of DHS activity, providing a targeted therapeutic strategy for cancers with high expression of DHS and eIF5A, and has great application prospects.
Smart Images

Figure CN119055628A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and relates to a small molecule inhibitor targeting protein activity and application thereof; in particular, relates to the application of a small molecule inhibitor targeting human deoxyhypusine synthase (DHS) activity. Background Art
[0002] Proteins are a major class of substances that are indispensable for maintaining the normal life activities of organisms. The coordinated action of multiple proteins in cells promotes the normal functioning of biological functions. However, the abnormal expression of certain genes disrupts the normal functioning of the intracellular signaling network, affects the normal proliferation of cells, and leads to the malignant progression of cancer. At present, the treatment strategy for cancer has gradually shifted from chemotherapy drugs to the strategy of using targeted drugs as much as possible. Therefore, functional inhibition research on overexpressed proteins in cancer is an effective strategy for drug development.
[0003] Gastric cancer, cervical cancer, ovarian cancer, colorectal cancer, and pancreatic cancer are all highly prevalent malignant tumors; studies have shown that there is a key protein in the malignant progression of these cancers - the eIF5A protein. The eIF5A protein is a highly conserved protein in eukaryotes and plays a role in the translation of most proteins. The hypusine residue of eIF5A can interact with the tRNA receptor arm to relieve the translation arrest caused by the polyproline motif. It has been found that eIF5A promotes the epithelial-mesenchymal transition of tumor cells and promotes cell invasion and metastasis. eIF5A must undergo post-translational modification to function, modifying Lys50 to Hpu50.
[0004] DHS is the first key protein to catalyze this post-translational modification. DHS generates Deoxyhypusine by transferring the butylamine group of spermidine to Lys50 of eIF5A, and then the residue is finally modified to hypusine under the catalysis of DOHH. DHS protein catalyzes the post-translational modification of eIF5A, leading to the production of mature eIF5A. Mature eIF5A can alleviate the ribosome arrest of the proto-oncogene MYC during expression and promote MYC elongation. It can also positively feedback regulate cancer metastasis-related pathways such as PEAK1 and RhoA.
[0005] By blocking the maturation of eIF5A, the development of malignant tumors can be inhibited, so it is meaningful to conduct research on the inhibition of DHS enzyme activity. At present, patients with neuroblastoma, colon cancer and other cancers with high expression of DHS and eIF5A have poor prognosis and low survival rate, so targeting DHS to inhibit eIF5A maturation is a very good treatment strategy. In addition, there are no inhibitors for DHS in clinical practice. GC-7 and CNI-1493 were synthesized as DHS inhibitors in the last century, but have not been used in cancer treatment. Therefore, small molecule inhibitors for DHS are still very scarce, so it is necessary to develop drugs for this target. Summary of the invention
[0006] In view of the above technical problems, the present invention provides a novel small molecule inhibitor for inhibiting the activity of DHS, thereby providing a potential drug for the clinical treatment of related diseases.
[0007] The technical solution provided by the present invention is as follows:
[0008] In the first aspect, the present invention provides the use of a small molecule inhibitor in the preparation of a drug for inhibiting the activity of deoxyhydroxyputrescine lysine synthase. The structure of the small molecule is as follows:
[0009]
[0010]
[0011] Furthermore, the DHS protein is a human DHS protein, a key protein in the post-translational modification process of eIF5A.
[0012] Furthermore, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 50: 1 to 100: 1. Preferably, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 80: 1 to 100: 1.
[0013] In a second aspect, the present invention provides a method for using the small molecule described in the first aspect to inhibit DHS enzyme activity, the specific steps are as follows:
[0014] 1. Construction of DHS prokaryotic gene plasmid
[0015] The DHS gene sequence was inserted into the pET28a plasmid through the BamHI and XhoⅠ restriction sites to construct the pET28a-His-DHS plasmid, which was verified by DNA sequencing;
[0016] 2. Expression of DHS fusion protein
[0017] The plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin, cultured to the logarithmic growth phase, induced by adding isopropylthiogalactoside (IPTG), and then collected by centrifugation;
[0018] 3. Purification of DHS fusion protein
[0019] The bacterial sludge collected in step 2 was resuspended with lysis buffer, lysed by ultrasonic method, and then the lysate was centrifuged and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human DHS fusion protein;
[0020] 4. Enzyme activity test of DHS protein
[0021] Each well of the plate was added with His-DHS protein and NAD + Preheat the protein reaction solution. At the same time, prepare the substrate reaction solution containing different gradient concentrations of spermidine (Spd) and add it to the well plate, and put it into the incubator for preheating. There are two rows of samples in total, with two replicate wells for each concentration. After preheating, use a spray gun to take the substrate reaction solution and add it to the protein reaction solution. After mixing, quickly enter the microplate reader for detection.
[0022] 5. Effects of DMSO and incubation time on enzyme activity
[0023] EP tubes are prepared with His-DHS protein and NAD + Take out the protein reaction solution and incubate it in the order of 90min, 70min, 50min, 30min, 10min, and 0min. Prepare the substrate reaction solution containing spermidine (Spd) and put it in the incubator for preheating. After the last sample is incubated, add 6 samples to row A, with two replicates for each sample. Use a spray gun to take 100μl of the substrate reaction solution and add it to row A. After mixing, quickly enter the microplate reader for detection.
[0024] EP tubes contain His-DHS protein and NAD +Prepare the protein reaction solution in the order of incubation for 90min, 50min, and 10min. Prepare two samples for each incubation time, namely the protein reaction solution and the protein reaction solution (0.2% DMSO). Put the two samples into the 37°C incubator at the same time. There are 6 samples in total for 3 incubation times. Prepare the substrate reaction solution containing spermidine (Spd) and put it into the incubator to preheat at 37°C for 5min. There are two rows of samples in total, with two replicates for each sample. After the last group of samples is incubated, add the 6 samples to row A of the 96-well plate. Use a spray gun to take 100μl of the substrate reaction solution and add it to row A. After mixing, quickly enter the microplate reader for detection.
[0025] 6. Verification of inhibitor activity
[0026] EP tubes contain His-DHS protein and NAD + Protein reaction solution. Add DMSO (0.2%) to the protein reaction solution of the negative control group. Add small molecule master solution (DMSO dissolved to 100mM) to the protein reaction solution of the experimental group and put it into a 37℃ incubator for incubation for 10 minutes. Prepare a substrate reaction solution containing spermidine (Spd) and put it into an incubator for preheating at 37℃ for 5 minutes. There are two rows of samples above, with two replicates for each sample. After incubation, use a spray gun to take the substrate reaction solution and add it to the protein reaction solution. After mixing, quickly enter the microplate reader for detection.
[0027] 7. Verification of covalent inhibition activity
[0028] The experiment was carried out according to the system in step 6, and the incubation time of the protein and small molecule was changed to 50 min and 90 min, showing a time gradient. Finally, the three groups of experiments with incubation time of 10 min, 50 min, and 90 min were compared together.
[0029] Inhibition (%) = (1-ΔRFU (molecule) / ΔRFU (DMSO)) * 100.
[0030] 8. MALDI-TOF covalent verification
[0031] Blank group: His-DHS was mixed with DMSO;
[0032] Experimental group: His-DHS was mixed with small molecule stock solution;
[0033] Incubate at 37°C for 1 h;
[0034] The reaction system was diluted with 0.1% TFA to make the final concentration of His-DHS 0.4-1.0 mg / ml;
[0035] Take 5 μl of the diluted reaction system and mix it with 5 μl of SA matrix;
[0036] 1 μl of the mixed sample was spotted on a metal target plate and subjected to mass spectrometry;
[0037] Use flex Control software to collect data and flex Analysis software to process data;
[0038] The lysis buffer in step 3 is: 50 mM Tris / HCl, pH=8.0, 300 mM NaCl, 300 mM imidazole;
[0039] The reaction solution composition in step 4 is: pH = 7.4, 137mM NaCl, 10mM Na2HPO4, 2mM KH2PO4
[0040] In step 8, 0.1% (v / v) TFA is: 5 μl TFA added to 5 ml UP H2O; TA30 is: 300 μl acetonitrile mixed with 700 μl 0.1% TFA; SA matrix is: a saturated solution of SA (sinapic acid) in TA30.
[0041] According to the above scheme, small molecules with potential inhibitory activity were screened experimentally.
[0042] The effective effects of the present invention are as follows:
[0043] The novel small molecule inhibitor for inhibiting DHS activity provided by the present invention has been shown to have a good effect of inhibiting DHS activity through testing. The inhibitor provides a targeted treatment strategy for the clinical treatment of neuroblastoma, colon cancer and other cancers with high expression of DHS and eIF5A, has great application prospects, and can also expand treatment methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 Validate the flow chart for the relevant tests;
[0045] Figure 2 The present invention is to verify the reaction activity of DHS protein with substrates of different concentrations in Example 1;
[0046] Figure 3 (Left) shows the effect of different incubation times on DHS enzyme activity in Example 1; Figure 3 (Right) shows the effect of DMSO on DHS enzyme activity in Example 1;
[0047] Figure 4 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 1; Figure 4 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 1 after incubation with the protein for different time periods; Figure 4(right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 1;
[0048] Figure 5 (Left) is a graph showing the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 2; 295 (middle) is a graph showing the inhibitory effect of the small molecule inhibitor in Example 2 after incubation with the protein for different time periods; Figure 5 (right) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 2;
[0049] Figure 6 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 3; Figure 6 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 3 after incubation with the protein for different time periods; Figure 6 (right) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 3;
[0050] Figure 7 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 4; Figure 7 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 4 after incubation with the protein for different time periods; Figure 7 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 4;
[0051] Figure 8 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 5; Figure 8 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 5 after incubation with the protein for different time periods; Figure 8 (right) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 5;
[0052] Fig. 9 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 6; Fig. 9 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 6 after incubation with the protein for different time periods; Fig. 9 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 6;
[0053] Fig.10 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 7; Fig.10 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 7 after incubation with the protein for different time periods; Fig.10 (right) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 7;
[0054] Fig.11 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 8; Fig.11(Middle) shows the inhibitory effect of the small molecule inhibitor in Example 8 after incubation with the protein for different time periods; Fig.11 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 8;
[0055] Fig.12 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 9; Fig.12 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 9 after incubation with the protein for different time periods; Fig.12 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 9;
[0056] Fig.13 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 10; Fig.13 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 10 after incubation with the protein for different time periods; Fig.13 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 10;
[0057] Fig.14 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 11; Fig.14 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 11 after incubation with the protein for different time periods; Fig.14 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 11;
[0058] Fig.15 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 12; Fig.15 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 12 after incubation with the protein for different time periods; Fig.15 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 12;
[0059] Fig.16 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 13; Fig.16 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 13 after incubation with the protein for different time periods; Fig.16 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 13;
[0060] Fig.17 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 14; Fig.17 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 14 after incubation with the protein for different time periods; Fig.17 (right) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 14;
[0061] Fig.18 (Left) shows the inhibitory effect of the small molecule inhibitor on DHS enzyme activity in Example 15; Fig.18 (Middle) shows the inhibitory effect of the small molecule inhibitor in Example 15 after incubation with the protein for different time periods; Fig.18 (Right) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 15. DETAILED DESCRIPTION
[0062] The present invention is further described below in conjunction with specific embodiments, but the content of the present invention is not limited thereto at all.
[0063] Example 1
[0064] The small molecule inhibitor involved is: Compound 1, the structural formula is as follows:
[0065]
[0066] The activity detection method is as follows:
[0067] 1. Construction of human DHS prokaryotic gene plasmid
[0068] The DHS gene sequence was inserted into the pET 28a plasmid through the BamHI and XhoⅠ restriction sites to construct the pET28a-His-DHS plasmid, which was verified by DNA sequencing.
[0069] Human DHS gene sequence:
[0070]
[0071] 2. Expression of human DHS protein
[0072] The plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin, and cultured at 37°C and 200 rpm until the logarithmic growth phase. Isopropylthiogalactoside (IPTG) was added to a final concentration of 0.5 mM, and induced at 37°C for 4 h, followed by collection by centrifugation.
[0073] 3. Purification of DHS fusion protein
[0074] The bacterial sludge collected in step 2 was resuspended with lysis buffer, lysed by ultrasound, and then the lysate was centrifuged at 4°C and 10,000 rpm, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human DHS fusion protein. The elution buffer composition of DHS fusion protein was: 50mM tris (Tris) / HCl, pH=8.0, 300mM NaCl, 300mM imidazole.
[0075] 4. Enzyme activity test of DHS protein
[0076] Add 100 μl of 1 μM His-DHS protein and 25 μM NAD into each well of a 96-well plate. + The protein reaction solution was preheated at 37°C for 5 minutes. At the same time, 150 μl / well of substrate reaction solution containing 25 μM, 12.5 μM, 6.3 μM, 3.2 μM, 1.6 μM, and 0 μM spermidine (Spd) were prepared and placed in an incubator for preheating at 37°C. There are two rows of samples above, with two replicate wells for each concentration. After preheating, 100 μl of substrate reaction solution was taken with a spray gun and added to the protein reaction solution. After mixing, it was quickly put into the microplate reader for detection. The detection conditions are: 37°C, 15 minutes, 30 seconds / time, excitation light 295nm, emission light 441nm.
[0077] 5. Effects of DMSO and incubation time on enzyme activity
[0078] EP tubes contain 1 μM His-DHS protein and 25 μM NAD +Take out 300μl of protein reaction solution and put it into the 37℃ incubator in the order of incubation for 90min, 70min, 50min, 30min, 10min, and 0min, for a total of 6 samples. Prepare 150μl / well of substrate reaction solution containing 25μM spermidine (Spd) and put it into the incubator for preheating at 37℃ for 5min. There are two rows of samples above, with two replicates for each sample. After the last sample is incubated, add the 6 samples to row A. Use a spray gun to take 100μl of substrate reaction solution and add it to row A. After mixing, quickly enter the microplate reader for detection. The detection conditions are: 37℃, 15min, 30s / time, excitation light 295nm, emission light 441nm.
[0079] EP tubes contain 1 μM His-DHS protein and 25 μM NAD + Prepare the protein reaction solution in the order of incubation for 90min, 50min, and 10min. Prepare two samples for each incubation time, namely protein reaction solution and protein reaction solution (0.2% DMSO), and put the two samples into the 37°C incubator at the same time. There are 6 samples in total for 3 incubation times. Prepare 150μl / well of substrate reaction solution containing 25μM spermidine (Spd) and put it into the incubator for preheating at 37°C for 5min. There are two rows of samples in total, with two replicates for each sample. After the last group of samples is incubated, add the 6 samples to row A of the 96-well plate. Use a spray gun to take 100μl of substrate reaction solution and add it to row A. After mixing, quickly enter the microplate reader for detection. The detection conditions are: 37°C, 15min, 30s / time, excitation light 295nm, emission light 441nm.
[0080] 6. Verification of inhibitor activity
[0081] EP tubes were prepared with 1 μM His-DHS protein and 25 μM NAD + 150μl of protein reaction solution. 0.2μl DMSO (0.2%) was added to the protein reaction solution of the negative control group. 0.2μl of small molecule master solution (DMSO dissolved to 100mM) was added to the protein reaction solution of the experimental group and placed in a 37℃ incubator for incubation for 10min. Prepare 150μl / well of substrate reaction solution containing 25μM spermidine (Spd) and place it in an incubator for preheating at 37℃ for 5min. There are two rows of samples above, with two replicate wells for each sample. After incubation, use a spray gun to take 100μl of substrate reaction solution and add it to the protein reaction solution row. After mixing, quickly enter the microplate reader for detection. The detection conditions are: 37℃, 15min, 30s / time, excitation light 295nm, emission light 441nm.
[0082] 7. Verification of covalent inhibition activity
[0083] The experiment was carried out according to the system in step 6, and the incubation time of the protein and small molecule was changed to 50 min and 90 min, showing a time gradient. Finally, the three groups of experiments with incubation time of 10 min, 50 min, and 90 min were put together for comparison of inhibition rates.
[0084] Inhibition (%) = (1-ΔRFU (molecule) / ΔRFU (DMSO)) * 100.
[0085] 8. MALDI-TOF covalent verification
[0086] Blank group: 10 μl of His-DHS was mixed with 0.2 μl of DMSO;
[0087] Experimental group: 10 μl of His-DHS was mixed with 0.2 μl of small molecule stock solution;
[0088] Incubate at 37°C for 1 h;
[0089] The reaction system was diluted with 0.1% TFA to make the final concentration of His-DHS 0.4-1.0 mg / ml;
[0090] Take 5 μl of the diluted reaction system and mix it with 5 μl of SA matrix;
[0091] 1 μl of the mixed sample was spotted on a metal target plate and subjected to mass spectrometry;
[0092] Use flex Control software to collect data and flex Analysis software to process data;
[0093] The test results are as follows:
[0094] Figure 4 (Left) shows that the inhibitory effect gradually increases with time.
[0095] Figure 4 (Middle) shows that the inhibitory effect gradually increases with time.
[0096] Figure 4 (Right) shows that the molecular weight mass spectrum peaks of the experimental group (gray) with small molecules added overlap with those of the blank group (black), from which it can be judged that the small molecule and the protein are not covalently bound (if the mass spectrum peak of the experimental group shifts to the right, it can be judged that the small molecule and the protein are covalently bound).
[0097] Example 2
[0098] The small molecule inhibitor involved is: Compound 2, the structure of which is shown below:
[0099]
[0100] The activity test method is the same as in Example 1.
[0101] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0102] Example 3
[0103] The small molecule inhibitor involved is: Compound 3, the structural formula of which is shown below:
[0104]
[0105] The activity test method is the same as in Example 1.
[0106] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0107] Example 4
[0108] The small molecule inhibitor involved is: Compound 4, the structural formula is as follows:
[0109]
[0110] The activity test method is the same as in Example 1.
[0111] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0112] Example 5
[0113] The small molecule inhibitor involved is: Compound 5, the structural formula is as follows:
[0114]
[0115] The activity test method is the same as in Example 1.
[0116] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0117] Example 6
[0118] The small molecule inhibitor involved is: Compound 6, with the following structural formula:
[0119]
[0120] The activity test method is the same as in Example 1.
[0121] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0122] Example 7
[0123] The small molecule inhibitor involved is: Compound 7, the structural formula is as follows:
[0124]
[0125] The activity test method is the same as in Example 1.
[0126] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0127] Example 8
[0128] The small molecule inhibitor involved is: Compound 8, the structural formula is as follows:
[0129]
[0130] The activity test method is the same as in Example 1.
[0131] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0132] Example 9
[0133] The small molecule inhibitor involved is: Compound 9, the structural formula is as follows:
[0134]
[0135] The activity test method is the same as in Example 1.
[0136] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0137] Example 10
[0138] The small molecule inhibitor involved is: Compound 10, the structural formula is as follows:
[0139]
[0140] The activity test method is the same as in Example 1.
[0141] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0142] Embodiment 11
[0143] The small molecule inhibitor involved is: Compound 11, the structural formula is as follows:
[0144]
[0145] The activity test method is the same as in Example 1.
[0146] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0147] Example 12
[0148] The small molecule inhibitor involved is: Compound 12, the structural formula is as follows:
[0149]
[0150] The activity test method is the same as in Example 1.
[0151] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0152] Embodiment 13
[0153] The small molecule inhibitor involved is: Compound 13, the structural formula is as follows:
[0154]
[0155] The activity test method is the same as in Example 1.
[0156] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0157] Embodiment 14
[0158] The small molecule inhibitor involved is: Compound 14, the structural formula is as follows:
[0159]
[0160] The activity test method is the same as in Example 1.
[0161] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0162] Embodiment 15
[0163] The small molecule inhibitor involved is: Compound 15, the structural formula is as follows:
[0164]
[0165] The activity test method is the same as in Example 1.
[0166] The test results were similar to those in Example 1, and the small molecule inhibitor showed good inhibitory effect.
[0167] The above description is only a preferred specific implementation manner of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention should be included in the scope of protection of the invention.
Claims
1. The use of a small molecule inhibitor in the preparation of a drug for inhibiting the activity of deoxyhydroxyputrescine lysine synthase, characterized in that: The structure of the small molecule is as follows:
2. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting the activity of deoxyhydroxyputrescine lysine synthase, characterized in that: The deoxyhydroxyputrescine lysine synthase is a human deoxyhydroxyputrescine lysine synthase.
3. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting the activity of deoxyhydroxyputrescine lysine synthase, characterized in that: The molar concentration ratio of the small molecule inhibitor in the final reaction volume is in the range of small molecule inhibitor:protein=50:1-100:1.
